

ASX ANNOUNCEMENT

ADMEDUS APPOINTS NEW CHAIRMAN

- Mr Wayne Paterson appointed new Admedus Chairman following the resignation of Mr Chris Catlow and Director Mr Graeme Rowley
- Collective expertise of the current board fully aligned with Admedus' medtech and biotech focus

Brisbane, Australia 9 February 2016

Admedus Limited (ASX: AHZ) has today announced that the Board has appointed Mr Wayne Paterson as Non-Executive Chairman with immediate effect. This follows the resignation of Mr Chris Catlow who held that position for 5 years. Mr Graeme Rowley, who served as a non-executive Director for 5 years, has also resigned. Messrs Catlow and Rowley have also been involved with the Group for the past 11 years holding non-executive director positions for subsidiary companies.

"The Board and I would like to thank Chris and Graeme for their work in establishing Admedus and their help in growing it into the diversified healthcare company it is today. Their contributions have been invaluable over the years", said incoming Chair Wayne Paterson. "The board now looks forward to applying our collective energies to the next chapter of Admedus' development and further improving patient outcomes and as a result shareholder value".

CEO Lee Rodne commented that, "the Admedus board now consists of directors with extensive experience in each of our core product areas with specific backgrounds in sales, marketing, general management and corporate governance. We look forward to their ongoing input to our outstanding management team."

Mr Paterson joined the Admedus board in 2015 having spent 25 years in the Global Pharmaceutical industry managing diverse and complex global operations at Roche and Merck. Over his career he has been responsible for substantial revenues and operations and held the positions of President Europe, Canada and Australia, President of Emerging markets, President of Japan, Global head of Cardiovascular and general medicine amongst others. Mr Paterson is also a Non-Executive Director of a NASDAQ listed molecular diagnostics company.

Biographical information on all directors can be found on the Company's website at www.Admedus.com

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC

Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com